MAPT and Alzheimer disease: In this regard, it has been proven that, in early AD, CSF YKL-40 is associated with a cerebral structural signature distinct from that related to p-tau neurodegeneration [28], even when a positive correlation between the levels of the two biomarkers in the CSF is reported [23–25, 34].